Crescel Study Shows Bio-Botanical Technology Outperforms Rosacea Prescription Standard
Florida-based science and technology firm Crescel LLC has published a peer-reviewed clinical study, indexed in PubMed, demonstrating its bio-botanical technology achieved statistically significant improvements over the leading prescription standard of care for rosacea.
Crescel LLC, a Florida-based science and technology company, has announced the publication of a peer-reviewed clinical study demonstrating superior results for its bio-botanical technology compared to the leading prescription standard of care for rosacea. The study, indexed in PubMed and published in the Journal of Cosmetic Dermatology, utilized a randomized, double-blind, controlled trial to evaluate the company's proprietary microemulsion technology platform.
The research indicated that Crescel® Skin Renewal Cream reduced facial redness by 54% compared to 23% for the prescription treatment, and inflammatory lesions by 74% versus 17%. The study also reported an excellent safety profile for Crescel's product, with no observed negative side effects.
Rosacea affects over 400 million people globally and is a common chronic inflammatory skin condition. Crescel suggests the findings highlight the potential for American-developed, non-pharmaceutical healthcare innovations to improve health outcomes and address healthcare affordability challenges.
"Healthcare systems around the world are searching for innovative solutions that improve outcomes while reducing long-term costs," said Peter J. Passalacqua, Jr., Co-Founder, Chairman & CEO of Crescel. "Our peer-reviewed publication validates years of scientific research and reinforces our belief that breakthrough bio-botanical technologies can play an increasingly important role in the future of healthcare."